344 related articles for article (PubMed ID: 25814083)
41. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.
Druker BJ; Guilhot F; O'Brien SG; Gathmann I; Kantarjian H; Gattermann N; Deininger MW; Silver RT; Goldman JM; Stone RM; Cervantes F; Hochhaus A; Powell BL; Gabrilove JL; Rousselot P; Reiffers J; Cornelissen JJ; Hughes T; Agis H; Fischer T; Verhoef G; Shepherd J; Saglio G; Gratwohl A; Nielsen JL; Radich JP; Simonsson B; Taylor K; Baccarani M; So C; Letvak L; Larson RA;
N Engl J Med; 2006 Dec; 355(23):2408-17. PubMed ID: 17151364
[TBL] [Abstract][Full Text] [Related]
42. Twin pregnancy in a patient of chronic myeloid leukemia on imatinib therapy.
Meera V; Jijina F; Shrikande M; Madkaikar M; Ghosh K
Leuk Res; 2008 Oct; 32(10):1620-2. PubMed ID: 18420270
[TBL] [Abstract][Full Text] [Related]
43. Pregnancies in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitor.
Zhou L; You JH; Wu W; Li JM; Shen ZX; Wang AH
Leuk Res; 2013 Oct; 37(10):1216-21. PubMed ID: 23937984
[TBL] [Abstract][Full Text] [Related]
44. Chronic myeloid leukaemia in pregnancy: call for guidelines.
P P; Samal R; Ghose S
J Obstet Gynaecol; 2019 May; 39(4):582-583. PubMed ID: 30744447
[TBL] [Abstract][Full Text] [Related]
45. Additional chromosome abnormalities, BCR-ABL tyrosine kinase domain mutations and clinical outcome in Hungarian tyrosine kinase inhibitor-resistant chronic myelogenous leukemia patients.
Meggyesi N; Kozma A; Halm G; Nahajevszky S; Bátai A; Fekete S; Barta A; Ujj G; Lueff S; Sipos A; Adám E; Bors A; Reményi P; Masszi T; Tordai A; Andrikovics H
Acta Haematol; 2012; 127(1):34-42. PubMed ID: 22005133
[TBL] [Abstract][Full Text] [Related]
46. A significant proportion of patients with chronic myeloid leukemia and suboptimal response according to European Leukemia Net criteria have excellent prognosis without treatment change.
Rohon P; Faber E; Divoka M; Rozmanova S; Friedecky D; Jarosova M; Indrak K
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2013 Jun; 157(2):181-8. PubMed ID: 22660209
[TBL] [Abstract][Full Text] [Related]
47. Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era.
Gunnarsson N; Stenke L; Höglund M; Sandin F; Björkholm M; Dreimane A; Lambe M; Markevärn B; Olsson-Strömberg U; Richter J; Wadenvik H; Wallvik J; Själander A
Br J Haematol; 2015 Jun; 169(5):683-8. PubMed ID: 25817799
[TBL] [Abstract][Full Text] [Related]
48. Fertility and pregnancy in chronic myeloid leukemia: real-world experience from an Indian tertiary care institution.
R C; Malik PS; Sahoo RK; Sharawat S; Singh M; Garg V; Bhatia K; Kantak A; Kumar S; Kumar L
Ann Hematol; 2023 Aug; 102(8):2087-2096. PubMed ID: 37322094
[TBL] [Abstract][Full Text] [Related]
49. Educational session: managing chronic myeloid leukemia as a chronic disease.
Hochhaus A
Hematology Am Soc Hematol Educ Program; 2011; 2011():128-35. PubMed ID: 22160024
[TBL] [Abstract][Full Text] [Related]
50. Patients' and hematologists' concerns regarding tyrosine kinase-inhibitor therapy in chronic myeloid leukemia.
Jiang Q; Yu L; Gale RP
J Cancer Res Clin Oncol; 2018 Apr; 144(4):735-741. PubMed ID: 29380058
[TBL] [Abstract][Full Text] [Related]
51. Factors Associated With Tyrosine Kinase Inhibitor Initiation and Adherence Among Medicare Beneficiaries With Chronic Myeloid Leukemia.
Winn AN; Keating NL; Dusetzina SB
J Clin Oncol; 2016 Dec; 34(36):4323-4328. PubMed ID: 27998234
[TBL] [Abstract][Full Text] [Related]
52. Managing children with chronic myeloid leukaemia (CML): recommendations for the management of CML in children and young people up to the age of 18 years.
de la Fuente J; Baruchel A; Biondi A; de Bont E; Dresse MF; Suttorp M; Millot F;
Br J Haematol; 2014 Oct; 167(1):33-47. PubMed ID: 24976289
[TBL] [Abstract][Full Text] [Related]
53. Quality of Life and Long-Term Therapy in Patients with Chronic Myeloid Leukemia.
Flynn KE; Atallah E
Curr Hematol Malig Rep; 2016 Apr; 11(2):80-5. PubMed ID: 26879546
[TBL] [Abstract][Full Text] [Related]
54. Survival trends in childhood chronic myeloid leukaemia in Southern-Eastern Europe and the United States of America.
Karalexi MA; Baka M; Ryzhov A; Zborovskaya A; Dimitrova N; Zivkovic S; Eser S; Antunes L; Sekerija M; Zagar T; Bastos J; Demetriou A; Agius D; Florea M; Coza D; Polychronopoulou S; Stiakaki E; Moschovi M; Hatzipantelis E; Kourti M; Graphakos S; Pombo-de-Oliveira MS; Adami HO; Petridou ET
Eur J Cancer; 2016 Nov; 67():183-190. PubMed ID: 27677054
[TBL] [Abstract][Full Text] [Related]
55. [Chronic myelogenous leukemia].
Hochhaus A; La Rosée P; Eigendorff E; Ernst T
Internist (Berl); 2015 Apr; 56(4):333-43. PubMed ID: 25860113
[TBL] [Abstract][Full Text] [Related]
56. The combination of hydroxyurea and leucapheresis in the treatment of chronic myeloid leukaemia in pregnancy.
Fitzgerald JM; McCann SR
Clin Lab Haematol; 1993; 15(1):63-5. PubMed ID: 8472499
[TBL] [Abstract][Full Text] [Related]
57. Prognostic scores for patients with chronic myeloid leukemia under particular consideration of competing causes of death.
Pfirrmann M; Lauseker M; Hoffmann VS; Hasford J
Ann Hematol; 2015 Apr; 94 Suppl 2():S209-18. PubMed ID: 25814087
[TBL] [Abstract][Full Text] [Related]
58. Hematopoietic cell transplantation in chronic myeloid leukemia in the age of tyrosine kinase inhibitors.
Copelan EA; Grunwald MR; Ghosh N; Plesca D; Trivedi J; Avalos BR
Discov Med; 2015 Mar; 19(104):213-8. PubMed ID: 25828525
[TBL] [Abstract][Full Text] [Related]
59. Maternal, Fetal, and Neonatal Imatinib Levels With Treatment of Chronic Myeloid Leukemia in Pregnancy.
Burwick RM; Kuo K; Brewer D; Druker BJ
Obstet Gynecol; 2017 May; 129(5):831-834. PubMed ID: 28383372
[TBL] [Abstract][Full Text] [Related]
60. Tyrosine kinase inhibitors and allogeneic hematopoietic cell transplantation for chronic myeloid leukemia: targeting both therapeutic modalities.
Fernandez HF; Kharfan-Dabaja MA
Cancer Control; 2009 Apr; 16(2):153-7. PubMed ID: 19337201
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
